CACNA1B and non-small cell lung carcinoma: Zhou et al. investigated an N-type VGCC (Cav2.2) in NSCLC, where increased Cav2.2 expression was revealed in 51% of lung adenocarcinomas, and was even higher in squamous (63%) and adenosquamous (89%) subtypes [34].